Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b–Literature Review and Personal Preliminary Experience
The inflammatory response to COVID-19 is specifically associated with an impaired type I interferon (IFN) response and complete blockade of IFN-β secretion. Clinically, nebulization of IFN-α-2b has been historically used in China to treat viral pneumonia associated with SARS-CoV. Very recent data sh...
Main Authors: | Aurélien Mary, Lucie Hénaut, Pierre Yves Macq, Louise Badoux, Arnaud Cappe, Thierry Porée, Myriam Eckes, Hervé Dupont, Michel Brazier |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.592543/full |
Similar Items
-
Effective nebulization of interferon-γ using a novel vibrating mesh
by: Louise Sweeney, et al.
Published: (2019-04-01) -
Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?
by: Aurélien Mary, et al.
Published: (2020-05-01) -
Current possibilities for nebulizer therapy
by: A. A. Zaytsev, et al.
Published: (2019-12-01) -
The emerging role of nebulization for maintenance treatment of chronic obstructive pulmonary disease at home
by: Deepak Talwar, et al.
Published: (2021-01-01) -
Nebulized Therapies in COPD: Past, Present, and the Future
by: Barjaktarevic IZ, et al.
Published: (2020-07-01)